Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

GUCY1A2 (P33402) - Overview - Molecular Target Synopsis

Protein


GUCY1A2, Guanylate cyclase soluble subunit alpha-2
Enzyme Classification 4.6.1.2
UniProt P33402

Also Known as GCYA2_HUMAN, GUCY1A2, GUC1A2, GUCSA2

Has guanylyl cyclase on binding to the beta-1 subunit., Isoform 2 acts as a negative regulator of guanylyl cyclase activity as it forms non-functional heterodimers with the beta subunits. Heterodimer of an alpha and a beta chain.

Isoforms / Transcripts (Protein Coding)


Drugs


GUCY1A2 is targeted by Approved Drugs Riociguat, Isosorbide Dinitrate. (see details)
Riociguat
Isosorbide Dinitrate

Sub-cellular localization


UniProt: GUCY1A2 is active in the following subcellular-locations: cytoplasm.
GO terms: GUCY1A2 is active in the following subcellular-locations: cytoplasm.



UniProt
GO terms

Gene Copy Number Variation


In COSMIC - Cell Lines Project GUCY1A2 has gain in 6 cell-lines, loss in 7 cell-lines and no signal in 992 cell-lines. (see details)

Gene Expression


In NCI60, the highest expressing cell lines are: BT_549, UACC_62, LOXIMVI

In Array Express (RNA-seq of 675 commonly used human cancer cell lines), the highest expressing cell lines are: NCI-H847, HCC33, MDA-MB-453

In Array Express (RNA-seq of long poly adenylated RNA and long non poly adenylated RNA from ENCODE cell lines), the highest expressing cell lines are: SK-N-SH, NHLF, HSMM

(see details)

3D Structures


At greater than 75% identity similarity to GUCY1A2 there are:
2 structures (3 chains) solved
0 are solved in complex with at least one small molecule ligand



(see details)
Molecular Target 3D Synopsis

Screening and Chemistry


GUCY1A2 has been screened with 136 compounds (177 bioactivities), 22 compounds have bioactivities that show binding affinity of <= 500nM (27 bioactivities). (see details)